PSNL News and Press, Personalis Inc. From 08/29/23

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21 st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton...

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subje...

2023-08-08 23:24:10 ET Personalis, Inc. (PSNL) Q2 2023 Earnings Conference Call August 08, 2023 05:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conferenc...

2023-08-08 17:04:02 ET Personalis press release ( NASDAQ: PSNL ): Q2 GAAP EPS of -$0.50 beats by $0.04 . Revenue of $16.7M (-8.2% Y/Y) beats by $0.21M . Cash, cash equivalents, and short-term investments of $137.2 million as of June 30, 2023. Third Quar...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with National Cancer Center H...

2023-08-07 17:35:16 ET Personalis ( NASDAQ: PSNL ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.54 (+10.0% Y/Y) and the consensus Revenue Estimate is $16.49M (-9.4% Y/Y). Over the last 1 year...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2023 financial results on Tuesday, August 8, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p....

2023-06-26 17:28:00 ET Personalis ( NASDAQ: PSNL ) said Monday that it has filed a second patent infringement suit against Foresight Diagnostics Inc. in the U.S. District Court for the District of Colorado. Personalis is seeking injunctive relief and monetary damages. ...

Infringed patents part of industry-leading intellectual property position in whole genome, tumor-informed minimal residual disease testing Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Pers...

Personalis, Inc. (Nasdaq: PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having p...